Blood Res 2014; 49(1): 65-66
Acute myeloid leukemia arising from chronic myelomonocytic leukemia during hypomethylating therapy
Pasquale Niscola*, Andrea Tendas, Laura Scaramucci, Marco Giovannini, Daniela Piccioni, and Paolo de Fabritiis

Hematology Division, S. Eugenio Hospital, Rome, Italy.

Correspondence to: Correspondence to: Pasquale Niscola. Hematology Division, S. Eugenio Hospital, Piazzale dell'Umanesimo 10, 00144, Rome, Italy.
Received: September 10, 2013; Revised: November 1, 2013; Accepted: February 19, 2014; Published online: March 24, 2014.
© The Korean Journal of Hematology. All rights reserved.

cc This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

TO THE EDITOR: Acute myeloid leukemia (AML) arising from chronic myelomonocytic leukemia (CMML) exhibits a poor prognosis [1, 2] and represents a great challenge during hematological clinical practice. The introduction of hypomethylating therapies, such as azacitidine [3, 4] and decitabine [5], in CMML management has provided some important advances; however, currently the majority of CMML cases progress into AML. We present the characteristics of 2 patients, in whom the atypical and sudden progression from CMML to AML was observed when they were administered azacitidine. Previously, both cases had achieved a very good response to this agent.

The first case is a 60-year-old man with a suspected therapy-related CMML, which arose 3 years after receiving chemo-radiotherapy treatment for a solid head and neck tumor. When diagnosed as having CMML, hypercellular bone marrow (BM) with 15% blasts was noted. Furthermore, the JAK2 V617F mutation was identified by quantitative PCR analysis, whereas standard cytogenetic and FISH analysis using BM and peripheral blood showed no abnormalities (normal karyotype). The MD Anderson Prognostic Scoring System (MDAPS) [6] classification was 4 (high risk). The patient received azacitidine at a dosage of 75 mg/m2 for 5+2 days (excluding weekends) every 4 weeks. After the fourth cycle of azacitidine, complete remission (CR) of CMML (BM blasts <5%) was recorded, although the patient continued the treatment during allogeneic hematopoietic stem cell transplantation. However, soon after the sixth cycle of azacitidine, a sudden evolution into AML (myelomonoblastic subtype) occurred. A very rapid transition from near normal peripheral blood counts to a very marked level of blastic leukocytosis was observed within 4 days: the WBC count was 120×109/L and 70% of myelomonoblastic cells were positive for HLA-DR, CD4, CD13, CD15, CD33, CD64, CD45, CD34, CD56, and CD117. Furthermore, an abnormal karyotype, i.e., 46,XY,del(7)(q31)[7]/46, XY[13], was found. FISH analysis confirmed a deletion of the long arm of chromosome 7 in 80% of blastic cells. Molecular studies detected the previously observed JAK2 V617F mutation, as well as the IDH2 R172K mutation; however, no AML-related alterations, such as CBFb/MYH11, DEK/CAN, NPM1, FLT3, and RUNX1/ETO, were identified. The patient received 1 course of chemotherapy for AML but soon died of disease progression.

The second case was a 72-year-old-man who was attended to because of pancytopenia with monocytosis. A BM aspirate and trephine biopsy showed hypercellular BM with 18% blasts, resulting in a diagnosis of CMML. The JAK2 V617F mutation was detected and chromosomal analysis revealed an abnormal karyotype, i.e., 46,XY,inv(12)(p13.3q15). The patient was classified by MDAPS as high-risk. He was treated with azacitidine according to the same schedule reported above, achieving a hematological and cytogenetic CR after the sixth cycle. The hypomethylating regimen was continued for additional 7 cycles; however, before starting the fourteenth cycle, the patient complained of a sudden deterioration of his general condition. A marked peripheral blastosis (WBC=140×109/L) was identified and 90% of immature monoblasts were positive for the immunophenotype HLA-DR, CD15, CD33, CD64, CD45, CD34, CD56, and CD117. A diagnosis of AML (French-American-British classification: M5b) was made. The same karyotypic abnormality that had been detected when diagnosed as having CMML was again identified. Molecular studies showed no abnormalities. The patient's condition rapidly worsened, and he died a few days after AML diagnosis because of cardiac and pulmonary complications. He had not been able to receive any chemotherapeutic treatment.

In conclusion, we reported 2 atypical cases dealing with a sudden and devastating transformation of high-risk CMML into AML during azacitidine treatment while in CR. Although new effective treatments such hypomethylating agents have been introduced, CMML remains a severe and incurable disease, for which allogeneic hematopoietic stem cell transplantation represents the only potentially curative treatment [1]. The evolution into AML can be delayed, but not avoided, in patients treated with hypomethylators. Moreover, AML can arise from CMML during its natural course [1]. AML transformation during hypomethylating therapy for CMML is quite common because of the lack of response to the hypomethylating agent and/or of disease progression [3, 7, 8, 9]. The present 2 cases did not provide any evidence that hypomethylating therapy is related to leukemic transformation, clonal selection, or evolution into AML. However, what makes these cases unusual is that the evolution into AML occurred within a few days without any prodromal clinical signs or anticipatory hematological features. Although presented with negative prognostic features both patients achieved a good response to the treatment; however, the responses were transient (2 and 7 months, respectively), and the particularly devastating evolution into AML was characterized by a rapid and prominent leukemic spread and a rapidly fatal clinical course. The biological and clinical features of AML transformation in patients who have received hypomethylators is not fully elucidated and understood; hence, further research into this issue is required to optimize the salvage treatment in this very challenging setting.

  1. Parikh, SA, Tefferi, A. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol, 2012;87;610-619.
  2. Courville, EL, Wu, Y, Kourda, J, et al. Clinicopathologic analysis of acute myeloid leukemia arising from chronic myelomonocytic leukemia. Mod Pathol, 2013;26;751-761.
  3. Breccia, M, Voso, MT, Alimena, G. Chronic myelomonocytic leukemia treatment with azacitidine: what have we learned so far?. Leuk Res, 2013;37;204-205.
  4. Kim, YJ, Jang, JH, Kwak, JY, Lee, JH, Kim, HJ. Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations. Blood Res, 2013;48;87-98.
  5. Wijermans, PW, Ruter, B, Baer, MR, Slack, JL, Saba, HI, Lubbert, M. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). Leuk Res, 2008;32;587-591.
  6. Onida, F, Kantarjian, HM, Smith, TL, et al. Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients. Blood, 2002;99;840-849.
  7. Thorpe, M, Montalvao, A, Pierdomenico, F, Moita, F, Almeida, A. Treatment of chronic myelomonocytic leukemia with 5-Azacitidine: a case series and literature review. Leuk Res, 2012;36;1071-1073.
  8. Costa, R, Abdulhaq, H, Haq, B, et al. Activity of azacitidine in chronic myelomonocytic leukemia. Cancer, 2011;117;2690-2696.
  9. Fianchi, L, Criscuolo, M, Breccia, M, et al. High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study. Leuk Lymphoma, 2013;54;658-661.


This Article

Current Issue


Indexed/Covered by

Today : 257  /
Total : 284,703